JP2023527385A - 抗ｇｄ２ ｓａｄａコンジュゲート及びその使用 - Google Patents

抗ｇｄ２ ｓａｄａコンジュゲート及びその使用 Download PDF

Info

Publication number
JP2023527385A
JP2023527385A JP2022572657A JP2022572657A JP2023527385A JP 2023527385 A JP2023527385 A JP 2023527385A JP 2022572657 A JP2022572657 A JP 2022572657A JP 2022572657 A JP2022572657 A JP 2022572657A JP 2023527385 A JP2023527385 A JP 2023527385A
Authority
JP
Japan
Prior art keywords
dota
seq
lys
sada
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022572657A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021242848A5 (https=
JP2023527385A5 (https=
Inventor
ブライアン エイチ サンティッチ
ナイ－コン ヴイ チュン
マヒウディン アフメッド
Original Assignee
メモリアル スローン ケタリング キャンサー センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メモリアル スローン ケタリング キャンサー センター filed Critical メモリアル スローン ケタリング キャンサー センター
Publication of JP2023527385A publication Critical patent/JP2023527385A/ja
Publication of JPWO2021242848A5 publication Critical patent/JPWO2021242848A5/ja
Publication of JP2023527385A5 publication Critical patent/JP2023527385A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2022572657A 2020-05-27 2021-05-26 抗ｇｄ２ ｓａｄａコンジュゲート及びその使用 Pending JP2023527385A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063030591P 2020-05-27 2020-05-27
US63/030,591 2020-05-27
PCT/US2021/034230 WO2021242848A1 (en) 2020-05-27 2021-05-26 Anti-gd2 sada conjugates and uses thereof

Publications (3)

Publication Number Publication Date
JP2023527385A true JP2023527385A (ja) 2023-06-28
JPWO2021242848A5 JPWO2021242848A5 (https=) 2024-06-03
JP2023527385A5 JP2023527385A5 (https=) 2024-06-03

Family

ID=78722708

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022572657A Pending JP2023527385A (ja) 2020-05-27 2021-05-26 抗ｇｄ２ ｓａｄａコンジュゲート及びその使用

Country Status (7)

Country Link
US (1) US20230235087A1 (https=)
EP (1) EP4157293A4 (https=)
JP (1) JP2023527385A (https=)
CN (1) CN116194133A (https=)
AU (1) AU2021280272A1 (https=)
CA (1) CA3180445A1 (https=)
WO (1) WO2021242848A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11583588B2 (en) * 2017-05-05 2023-02-21 Memorial Sloan Kettering Cancer Center Modular self assembly disassembly (SADA) technologies
EP4448565A1 (en) 2021-12-15 2024-10-23 Y-Mabs Therapeutics, Inc. Scfv and antibodies with reduced multimerisation
JP2024546804A (ja) * 2021-12-15 2024-12-26 ワイ－マブス セラピューティクス， インコーポレイテッド Ｓａｄａ複合体を含む製剤
US20260021206A1 (en) * 2022-07-25 2026-01-22 Vironexis Biotherapeutics Inc. Adeno-associated virus vectors and methods of their use for reducing the risk of, treating, and preventing metastasis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010209098A (ja) * 2001-04-03 2010-09-24 Immunomedics Inc 二重特異性抗体とともに使用される新規なペプチド型薬剤の製造及び使用
WO2019178218A1 (en) * 2018-03-14 2019-09-19 Memorial Sloan Kettering Cancer Center Anti-polysialic acid antibodies and uses thereof
US20200155698A1 (en) * 2017-05-05 2020-05-21 Memorial Sloan Kettering Cancer Center Modular self assembly disassembly (sada) technologies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060057062A1 (en) * 2004-09-10 2006-03-16 Trotter Dinko G Compositions and methods useful in pretargeted imaging
US11565005B2 (en) * 2017-07-06 2023-01-31 Memorial Sloan Kettering Cancer Center Dota-hapten compositions for anti-dota/anti-tumor antigen bispecific antibody pretargeted radioimmunotherapy
AU2020225631A1 (en) * 2019-02-22 2021-09-16 Memorial Sloan Kettering Cancer Center CD33 antibodies and methods of using the same to treat cancer
EP3938400B1 (en) * 2019-03-11 2025-07-30 Memorial Sloan Kettering Cancer Center Cd22 antibodies and methods of using the same
CN114401744B (zh) * 2019-06-26 2024-11-05 纪念斯隆凯特琳癌症中心 用于治疗癌症的抗cd33抗体

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010209098A (ja) * 2001-04-03 2010-09-24 Immunomedics Inc 二重特異性抗体とともに使用される新規なペプチド型薬剤の製造及び使用
US20200155698A1 (en) * 2017-05-05 2020-05-21 Memorial Sloan Kettering Cancer Center Modular self assembly disassembly (sada) technologies
WO2019178218A1 (en) * 2018-03-14 2019-09-19 Memorial Sloan Kettering Cancer Center Anti-polysialic acid antibodies and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Preclinical Evaluation of Multistep Targeting of Diasialoganglioside GD2 Using an IgG-scFv Bispecifi", MOL CANCER THER, vol. 13(7), JPN6025011634, 2014, pages 1803 - 1812, ISSN: 0005763271 *
"Self-Assembling and DisAssembling Bispecific Antibodies for Curative 2-step Pretargeted Radioimmunot", JOURNAL OF NUCLEAR MEDICINE, vol. 61(supplement 1), 34, JPN6025011633, 1 May 2020 (2020-05-01), ISSN: 0005763269 *
RAFKE SCHOFFELEN ET AL.: "Pretargeted 177Lu Radioimmunotherapy of Carcinoembryonic AntigenExpressing Human Colonic Tumors in M", JOURNAL OF NUCLEAR MEDICINE, vol. 51, no. 11, JPN6025053969, November 2010 (2010-11-01), pages 1780 - 1787, ISSN: 0005763270 *

Also Published As

Publication number Publication date
EP4157293A4 (en) 2024-07-31
CN116194133A (zh) 2023-05-30
US20230235087A1 (en) 2023-07-27
EP4157293A1 (en) 2023-04-05
WO2021242848A1 (en) 2021-12-02
CA3180445A1 (en) 2021-12-02
AU2021280272A1 (en) 2023-01-19

Similar Documents

Publication Publication Date Title
EP1487879B1 (en) Bispecific antibody point mutations for enhancing rate of clearance
JP5138867B2 (ja) α−フェトタンパク質Ｉｍｍｕ３１抗体および融合タンパク質ならびにその使用方法
JP2023527385A (ja) 抗ｇｄ２ ｓａｄａコンジュゲート及びその使用
ES2838750T3 (es) Anticuerpos, composiciones y usos
ES2789573T3 (es) Anticuerpos multiespecíficos con afinidad por el antígeno A33 humano y el complejo metálico de DOTA
JP5919604B2 (ja) 抗膵癌抗体
US20210017295A1 (en) Bispecific binding agents and uses thereof
CA3219934A1 (en) Compositions and methods for the treatment of prostate cancer
JP2024519970A (ja) 三価放射性同位体生物標的放射性医薬品、調製方法及び使用
KR102866721B1 (ko) Dota-사전표적화된 방사면역요법을 위한 n-아세틸갈락토사미노 덴드론-제거제
TW202313115A (zh) Egfrviii靶向化合物及其用途
EP4317188A1 (en) Radioactive complex of anti-egfr antibody, and radiopharmaceutical
US20240216557A1 (en) Radioligand binding to anti-dll3 antibodies for pretargeted pet imaging and therapeutic uses thereof
EP4327831A1 (en) Radioactive complex of anti-cd20 antibody, and radiopharmaceutical
WO2025035107A2 (en) Trophoblast glycoprotein antibody compositions and methods of use
TW202606757A (zh) 用於治療前列腺癌之組成物及方法
TW202607033A (zh) 抗ｒｏｒ２抗體－放射性核種結合物
WO2025111661A1 (en) Novel radiolabelled antibodies
WO2025244971A1 (en) Compositions and methods for the treatment of prostate cancer
EA044225B1 (ru) Применение очищающего агента на основе дендронов n-ацетилгалактозамина в предварительно направленной радиоиммунотерапии с хелатором dota

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240524

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240524

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250321

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250324

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250624

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250922

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260402